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Abstract
Background: Negative symptoms are considered core symptoms of schizophrenia. The Brief Negative Symptom
Scale (BNSS) was developed to measure this symptomatic dimension according to a current consensus definition.
The present study examined the psychometric properties of the German version of the BNSS. To expand former
findings on convergent validity, we employed the Temporal Experience Pleasure Scale (TEPS), a hedonic self-report
that distinguishes between consummatory and anticipatory pleasure. Additionally, we addressed convergent
validity with observer-rated assessment of apathy with the Apathy Evaluation Scale (AES), which was completed by
the patient’s primary nurse.
Methods: Data were collected from 75 in- and outpatients from the Psychiatric Hospital, University Zurich
diagnosed with either schizophrenia or schizoaffective disorder. We assessed convergent and discriminant validity,
internal consistency and inter-rater reliability.
Results: We largely replicated the findings of the original version showing good psychometric properties of
the BNSS. In addition, the primary nurses evaluation correlated moderately with interview-based clinician rating.
BNSS anhedonia items showed good convergent validity with the TEPS.
Conclusions: Overall, the German BNSS shows good psychometric properties comparable to the original English
version. Convergent validity extends beyond interview-based assessments of negative symptoms to self-rated
anhedonia and observer-rated apathy.
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Background
The negative symptoms of schizophrenia consist of
flattened affect, alogia, social withdrawal, avolition, and
anhedonia [1]. They account to a large extent for
impairments of work and social functioning, as well as
longterm morbidity [2–4]. Today, pharmacological and
psychosocial interventions have limited efficacy for
reducing negative symptoms [5, 6].
The reliable and valid assessment of negative symptoms
is critical for the development of pathophysiological
models and effective treatments [7]. Since the introduc-
tion of quantitative assessment of negative symptoms in
the early 1980s, concepts of negative symptoms have
undergone subtle but important changes [8, 9]. Most
importantly, this includes the distinction of two main
factors of negative symptoms apathy/avolition and dimin-
ished expression [1, 10]. Other important shifts include
the definition of cognitive dysfunction as a separate symp-
tom dimension, the distinction between objective and
subjective aspects of apathy/avolition, and the separation
of consummatory and anticipatory anhedonia [9].
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A consensus conference in 2005 under the auspices of
the National Institute of Mental Health (NIMH) has
provided an integration of these developments into a
common conception of negative symptoms [9]. A main
outcome of this consensus conference was the agree-
ment that new instruments would have to be developed
in order to fully cover this modern conceptualization of
negative symptoms. Subsequently, two scales were devel-
oped – the Clinical Assessment Interview for Negative
Symptoms (CAINS) [11] and the Brief Negative Symptom
Scale (BNSS) [12]. The BNSS was explicitly intended for
easy application in the context of clinical trials or experi-
mental psychopathology studies. The BNSS is a 13-item
instrument, which allows rapid assessment of negative
symptoms based on a semi-structured interview. The
authors were able to establish excellent psychometric
properties in a series of validation studies [12–14]. Suc-
cessful translations have been accomplished for Spanish
and Italian versions of the BNSS, which also demonstrate
excellent psychometric properties [15, 16].
The present study aimed to establish reliability and
validity of the German version of the BNSS. In addition,
we expanded previous investigations of convergent valid-
ity by discriminating between self-reported anticipatory
and consummatory pleasure and by including observer-
based measures of apathy/avolition. First, in order to
assess whether the BNSS anhedonia subscales capture
the self-rated subjective experience of anhedonia, we
included the Temporal Experience of Pleasure Scale.
Second, we assessed the relationship between BNSS
ratings and observer-rated apathy/avolition by including
the Apathy Evaluation Scale rated by the primary nurse.
We also included the Modified Simpson-Angus Scale
(MSAS) as a measure for extrapyramidal side effects in
the estimation of divergent validity.
Methods
Participants
Seventy-five individuals meeting Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV)
criteria for schizophrenia (n = 65) or schizoaffective dis-
order (n = 10, not currently in a mood episode) were in-
cluded in the study. The local Ethics committee approved
the study, and all participants gave written informed consent.
Inclusion criteria were: (1) outpatient or inpatient
treatment at the Psychiatric Hospital, University of
Zurich, (2) a clinical diagnosis schizophrenia or schizoaf-
fective disorder and (3) age from 18 to 65 years. Import-
antly, all patients had to be clinically stable, i.e. they did
not show positive symptoms of more than moderate
severity (see exclusion criteria below) and received a
constant dose of antipsychotic medication for at least
two weeks prior to testing. Exclusion criteria were: (1)
daily lorazepam dosage > 1 mg, (2) positive symptoms of
moderate severity (Positive and Negative Syndrome
Scale (PANSS) [17]; any positive subscale item score >4),
(3) history of head injury or neurological disorder, (4)
insufficient German fluency (5) additional DSM-IV axis-
1 or axis-2 diagnostic criteria (according to the treating
clinician). To confirm axis-1 diagnosis in patients and
exclude comorbid axis-1 disorders, we used the Mini-
International Neuropsychiatric Interview [18]. All pa-
tients were treated with second-generation antipsychotic
medication.
Patients were either inpatients at the end of their
hospitalization (n = 49) or outpatients (n = 26) treated at
the Psychiatric Hospital, University of Zurich. Please
note that the average inpatient stay for patients with
schizophrenia in Swiss psychiatric hospitals is above
40 days [19]; as a consequence a lot of of our inpatients
would be treated as outpatients in different healthcare
systems. Notably, inpatients took part in a multimodal
treatment program and were encouraged to participate
in activities outside the hospital, which permitted assess-
ment of apathy/avolition symptoms. The The treatment
setting of our participants regularly includes a morning-
meeting after breakfast, activation groups and various
combinations of work-, occupational-, sports- and arts-
therapies. These therapies take place from Monday to
Friday during mornings and afternoons. Thus, the in-
patient treatment program is comparable to a day-care
setting. In addition to the group-based therapies, patients
have individual sessions with a physician and/or a psych-
ologist three times a week. Demographic information is
presented in Table 1.
Procedures
The primary instrument of interest was the Brief Nega-
tive Symptom Scale (BNSS) [12]. As mentioned in the
background section, the scale allows a rapid and reliable
assessment of negative symptoms. It consists of 13 items
and 6 subscales (anhedonia, distress, avolition, blunted
affect and alogia, see Table 2) and can be split into the
two different factors motivation and pleasure and
emotional expressivity [14]. The scale includes a compre-
hensive manual, a workbook and a score sheet, which all
have been translated into German. Negative symptoms
were also assessed with the Scale for the Assessment of
Negative Symptoms (SANS) [8], which is a widely used
scale including 4 subscales (affective flattening/blunting,
alogia, avolition/apathy and anhedonia/asociality).
The Global Assessment of Functioning scale (GAF)
[20] and the Personal and Social Performance Scale
(PSPS) [21] both measure functioning. However, the
latter excludes psychopathological aspects and is the-
refore a more specific instrument for functioning. The
Calgary Depression Scale for Schizophrenia (CDSS)
[22] is an interview-based instrument that has been
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developed to identify depressive symptoms in patients
with schizophrenia. The Positive and Negative Syn-
drome Scale (PANSS) [17] is a 30-item scale that is
split into three dimensions (negative symptoms, posi-
tive symptoms and general psychopathology including
depression and anxiety) and allows to capture a broad
range of symptomatology. However, based on recent
findings about the underlying structure of the PANSS,
a 5-factor model (positive, negative, disorganized/con-
crete, excited and depressed) described by Wallwork
et al. was used for all calculations [23].
The five clinical raters, who completed ratings for all
scales, were trained and regularly supervised by the
senior author. Raters were trained individually, which
included a step-by-step instruction on how to use the
scale, joint ratings of videos and live interviews and
conduction of supervised interviews. To increase interrater
reliability, raters were additionally trained in video-based
group sessions. Three of them have a masters-degree in
clinical psychology and two were psychiatrists in training.
The German version of the BNSS is based on a trans-
lation process including forward translation, back trans-
lation, and reconciliation of back translation with the
BNSS developers. This process therefore met the highest
industry standards. To extend the evaluation of conver-
gent/discriminant validity beyond the original English
BNSS studies, the Apathy Evaluation Scale (AES-C) [24]
was administered by the primary nurse for the inpatients
only. The AES-C was established to measure apathy for
neurological and psychiatric patients. The Temporal
Experience of Pleasure Scale (TEPS) [25] was filled out
by the patients for anhedonia self-report. It allows to
distinguish consummatory and anticipatory anhedonia
which is specifically important in the role of schizophrenia.
Finally, the Modified Simpson-Angus Scale (MSAS) [26]
was completed by the physician raters to evaluate extrapyr-
amidal symptoms.
To assess inter-rater reliability, two different assessors
rated 27 patients independently within the same session.
The raters attended the same interview in person but
were then separated to complete ratings.
Statistical analysis
To calculate correlations for convergent and discrimin-
ant validity, Pearson’s r was computed. A partial cor-
relation between negative symptoms (BNSS total) and
functioning (GAF) was conducted in order to control
the influence of common sources of secondary negative
symptoms on this association. Reliability was calculated
with Cronbach’s alpha for internal consistency and Intra-
class Correlation Coefficient (ICC) for inter-rater agree-
ment. Statistical analyses were performed using IBM
SPSS Statistics Version 21. A test for significant differ-
ences in the magnitude of the correlation between the
BNSS and the TEPS pleasure scales was performed using
Steiger’s method implemented in the online tool http://
quantpsy.org/corrtest/corrtest2.htm [27, 28].
Results
Descriptive statistics and distribution of scores
Descriptive statistics for BNSS items and subscales are
presented in Table 2. The lack of normal distress as well
as the quantity of speech items had skew > 1.0 indicating
distribution towards nonpathological ratings.
Internal consistency
Cronbach’s alpha, computed to analyze internal consistency,
was 0.93, indicating that the items measure a distinct
latent construct of negative symptoms. Item total corre-
lations showed that all BNSS items were significantly
correlated with the BNSS total scale score (Table 2).
Alpha if-item-deleted coefficients ranged from 0.92 to
0.93, with only the lack of normal distress item lower-
ing the value.
Inter-rater reliability
To assess inter-rater reliability (Table 2), Intraclass
Correlation Coefficients (ICCs) were calculated for the
BNSS total score and for each subscale. The ICC for the
BNSS total score was 0.97, and ICC values for the sub-
scales were: Anhedonia 0.88, distress 0.93, asociality
0.95, avolition 0.87, blunted affect 0.95, and alogia 0.97.
Table 1 Demographics (n = 75)
Mean (SD)
Age 31.5 10.9
Education (years) 11.6 2.9
Duration of illness (months) 133.2 224.1
Number of hospitalizations 4.7 3.9
% male 74.7
% inpatients (vs outpatients) 65.3
% Diagnosis Schizophrenia (vs Schizoaffective)
Antipsychotic treatment
86.7
% second generation 92.0
% first and second generation 4.0
% none 4.0
PANSS total 50.8 12 .3
PANSS positive factora 1.8 0.7
PANSS negative factora 2.3 1.0
PANSS disorganized factora 1.7 0.7
PANSS excited factora 1.2 0.4
PANSS depressed factora 1.7 0.8
CDSS total 1.8 2.2
GAF total 55.9 11.6
amean =mean per item
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Convergent validity with clinician-rated negative
symptoms and functioning
To assess convergent validity (Table 3) we used clinician
rated scales (SANS, PANSS). The BNSS total was strongly
correlated with the SANS Total (r = 0.89, p < 0.001) and
PANSS Negative factor (i.e., emotional withdrawal, poor
rapport, passive/apathetic social withdrawal, lack of
spontaneity and motor retardation) (r = 0.89, p < 0.001),
suggesting good convergent validity with other negative
symptom measures.
Good subscale-level convergent validity was indicated
by moderate to high correlations between BNSS subscale
scores and the average of items comprising the 4 subscales
of the SANS: BNSS anhedonia with SANS anhedonia/aso-
ciality (r = 0.58, p < 0.001); BNSS asociality with SANS
anhedonia/asociality (r = 0.79, p < 0.001); BNSS avolition
with SANS avolition (r = 0.79, p < 0.001); BNSS blunted
Affect with SANS blunted Affect (r = 0.93, p < 0.001); and
BNSS alogia with SANS alogia (r = 0.82, p < 0.001).
The BNSS lack of normal distress item was negatively
correlated with the PANSS depressed factor (r = −0.33,
p < 0.001), supporting the item’s validity.
The BNSS total score had a high inverse correlation with
the GAF total (r = -0.69, p < 0.001) score, as well as the PSP
total score (r = -0.70, p < 0.001), suggesting good convergent
validity with functional outcome. A partial correlation was
conducted, controlling for depression, anxiety, psychosis
and disorganization, to determine whether this association
remained significant when accounting for common sources
of secondary negative symptoms. The correlation between
the BNSS total and the GAF total remained highly signifi-
cant (r = -0.62, p < 0.001).
Convergent validity with self-rated anhedonia and
observer-rated apathy
The TEPS self-report scale (Table 3) was used for
convergent validity of the anhedonia subscale. The
self-report scale was filled out by a smaller subsample
Table 2 Descriptive statistics, item-total correlations, ICC’s
M SD Skew Kurtosis Item-total score r ICCb
Anhedonia
1. Intensity of pleasure during activities 2.3 1.6 0.1 -0.9 0.80**
2. Frequency of pleasurable activities 2.5 1.6 0.0 -0.8 0.78**
3. Intensity of future pleasure 2.1 1.5 0.4 -0.3 0.69** 0.88
Subscale total 7.1 4.4 0.1 -0.6
Distress subscale
4. Lack of normal distress 1.0 1.4 1.3a 0.7 0.51** 0.93
Asociality subscale
5. Asociality behavior 2.6 1.4 0.1 -0.3 0.70**
6. Asociality inner-experience 2.0 1.4 0.6 -0.3 0.71**
Subscale total 4.6 2.6 0.4 -0.3 0.95
Avolition subscale
7. Avolition behavior 2.5 1.3 0.0 -0.6 0.74**
8. Avolition inner-experience 2.1 1.5 0.2 -0.7 0.79**
Subscale total 4.7 2.7 0.2 -0.5 0.87
Blunted affect subscale
9. Facial expression 2.2 1.6 0.6 -0.4 0.85**
10. Vocal expression 2.0 1.7 0.6 -0.5 0.81**
11. Expressive gestures 2.1 1.7 0.4 -1.0 0.78**
Subscale total 6.3 4.7 0.6 -0.5 0.95
Alogia subscale
12. Quantity of speech 1.3 1.5 1.1a 0.9 0.72**
13. Spontaneous elaboration 1.5 1.7 0.9 0.0 0.75**
Subscale total 2.7 3.1 1.0 0.1 0.97
BNSS total score 26.3 14.7 0.7 0.1 0.97
aSkew towards nonpathological ratings
bn = 28, Two-way mixed model, absolute agreement definition, average measures
**p < 0.01
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(n = 66). The BNSS anhedonia subscale was negatively
correlated with both the anticipatory (r = −0.31, p < 0.05)
and consummatory (r = −0.36, p < 0.001) pleasure scales
from the TEPS. Regarding the attempt to discriminate
between anticipatory and consummatory pleasure, the
BNSS anticipatory (r = -0.26, p < 0.05) as well as the BNSS
intensity of pleasure item (r = -0.25, p < 0.05) were
correlated with the TEPS anticipatory pleasure scale. On
the other hand, only the BNSS consummatory (r = -0.29,
p < 0.05) but not the anticipatory item (r = -0.20, p > 0.05)
was correlated with the TEPS consummatory pleasure
scale. However, the two correlation coefficients were not
significantly different. The SANS anhedonia–asociality
scale was neither correlated with TEPS anticipatory pleas-
ure scale (r = −0.13, p > 0.05) nor the consummatory
pleasure scale (r = -0.15, p > 0.05). These results support
the convergent validity of the BNSS anhedonia items.
The AES observer scale (Table 3) was completed by
the inpatient’s primary nurse (n = 49) and correlated
moderately with the BNSS total score (r = 0.48, p < 0.001)
and the BNSS motivation/pleasure scale (i.e., average of
anhedonia, avolition, asociality items) (r = 0.50, p < 0.001).
Thus, BNSS ratings correspond well to apathy ratings by
the primary care person.
Discriminant validity
Discriminant validity (Table 4) of the BNSS was examined
by calculating correlations with positive symptoms, disor-
ganized symptoms, general symptoms, and extrapyramidal
side effects (MSAS). BNSS total was not significantly cor-
related with the PANSS positive factor (r = -0.02, p > 0.05),
PANSS depressed factor (r = 0.02, p > 0.05) or PANSS
excited factor (r = 0.19, p > 0.05). There was a modest
correlation between the PANSS disorganized factor and
the BNSS total score (r = 0.37, p < 0.001). This correlation
was mainly due to the Expression subscales (range
r = 0.40–0.42, p < 0.01), whereas no correlation with
the subscales of the Motivation and Pleasure factor
was observed (range r = -0.04 – 0.23, p > 0.05). However,
the mean score on the disorganization factor was 5.00
(2.12) (lowest possible 3) and the maximum score 10
(from 21 possible), therefore representing a non-
disorganized sample. The CDSS total score was not
significantly correlated with the BNSS total score (r = 0.16,
p > 0.05) or the BNSS anhedonia score (r = 0.08, p > 0.05).
Finally, the BNSS total score was not correlated with the
MSAS (r = 0.12, p > 0.05).
Discussion
Overall the German translation of the BNSS shows good
psychometric properties including inter-rater reliability,
which mostly replicate the findings for the original
version. Importantly, we show that overall the BNSS anhe-
donia subscales converge with self-reported anhedonia,
although the differentiation between anticipatory and con-
summatory anhedonia remains a challenge. In addition,
BNSS rated negative symptoms correlate with observer-
rated apathy as assessed by the primary nurse.
Convergent validity with the SANS total and the PANSS
negative factor was high and moderate to high for the re-
spective subscales. It has to be noted that the observed cor-
relations might be somewhat higher than expected, because
the same rater scored the BNSS and the other negative
symptom scales. Nevertheless, these results confirm the as-
sumption of a common and established construct for nega-
tive symptoms. We also found strong associations between
negative symptoms and functioning, emphasizing the im-
portance of its role as a predictor of poor outcome [2].
Table 3 Convergent validity
BNSS total BNSS motivation/pleasure BNSS diminished expression BNSS anhedonia
PANSS negative factor 0.89** 0.71** 0.90**
SANS avolition/apathy 0.63** 0.65** 0.47** 0.43**
SANS asociality/anhedonia 0.77** 0.80** 0.57** 0.58**
SANS blunted affect 0,82** 0.56** 0.91**
SANS alogia 0.63** 0.37** 0.77**
SANS total 0.89** 0.73** 0.87**
AES total (n = 48) -0.48** -0.50** -0.40**
GAF -0.69** -0.68** -0.56**
PSP total -0.73** -0.73** -0.57**
TEPS anticipatory TEPS consummatory
BNSS intensity of pleasure -0.25* -0.29*
BNSS intensity of future pleasure -0.26* -0.20
BNSS anhedonia subscale -0.31* -0.36*
SANS asociality/anhedonia -0.13 -0.15
Note. *p < 0.05; **p < 0.01
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For anhedonia, we could show incremental validity as
the TEPS scales only correlated with the BNSS anhedo-
nia scale, but not with the SANS anhedonia subscale.
This strongly suggests that BNSS anhedonia captures
the subjective experience of anhedonia better than older
negative symptom scales. The importance of the distinc-
tion between anticipatory and consummatory pleasure
has been emphasized, as only the former has been con-
sistently found to be impaired in patients with schizo-
phrenia [25]. We also addressed the question of whether
the individual BNSS anhedonia items show specific
correlations with the respective TEPS anticipatory and
consummatory subscales. However, this distinction was
limited, as all correlation coefficients were in a similar
range. Only the BNSS intensity of pleasure item seemed
to be somewhat more strongly related to the TEPS con-
summatory anhedonia subscale, but differences between
correlations were small and non-significant. The lack of
convergent validity between the TEPS subscales and
BNSS anhedonia items could reflect limitations of the
BNSS, TEPS, or both measures in evaluating consumma-
tory and anticipatory pleasure. The TEPS consummatory
and anticipatory pleasure subscales have shown some-
what diverging findings across studies, with some inves-
tigations showing a deficit in consummatory but not
anticipatory [29] and others an impairment in anticipa-
tory but not consummatory pleasure [25]. This raises
the question whether the TEPS was fully suited for
assessing the specific convergent validity of the items
with the anhedonia subscale. Also, the BNSS intensity
item may show restricted range and rely on memory
aspects that might be impaired in patients, suggesting
that few patients may have a true consummatory pleasure
deficit [30]. Thus, it remains an open question whether
the current convergent validity findings on anhedonia
reflect limitations of the scales or the conceptualization of
anhedonia as a consummatory vs. anticipatory pleasure
deficit in schizophrenia.
To expand prior work on convergent validity to a
different assessment modality, we included the AES as an
observer rating of apathy that was completed by the
patient’s primary nurse. We found moderate correlations
between AES ratings and BNSS total and motivation/
pleasure scores. This is quite remarkable, because the
nurses were not trained in the assessment of negative symp-
toms and were simply instructed to score the AES based on
their observations in daily life on the ward. Interview-based
assessments always raise the question whether the partici-
pant correctly reports his interests and activities [31], but
the present findings suggest a good convergence between
interview-based reports and observer ratings. Whether this
convergence generalizes to non-professional care-givers
such as relatives remains an open issue.
Discriminant validity was shown by excellent differenti-
ation between the BNSS and measures of positive symp-
toms and depression. It can therefore be concluded that
the BNSS clearly measures disturbances that are different
from other symptom dimensions of schizophrenia. In
addition, extrapyramidal side effects have been considered
as major cause for secondary negative symptoms. The
only study with the BNSS to have previously included a
measurement of extrapyramidal symptoms has taken a
categorical approach of present or absent extrapyramidal
side effects [16]. Here, we have employed a dimensional
approach, which shows that BNSS total and subscales
were not associated with extrapyramidal symptoms. This
is in line with the categorical findings by Mucci and
colleagues, thereby supporting discriminant validity.
Some limitations of the present study need to be consid-
ered. First, overall the participants showed relatively low
levels of positive, depressive, and extrapyramidal symp-
toms. Therefore, it is an important question whether the
excellent discriminant validity reported here generalizes to
populations with higher non-negative symptom levels.
Third, the inclusion criteria may impact the ability of
these findings to generalize to samples with greater stabil-
ity and comorbid substance use disorders. Finally, the
interpretation of convergent validity analyses is compli-
cated by the use of different different forms of assessment
(i.e., self-report questionnaires vs. clinician rated) and
different types of raters (e.g., nurse vs. clinician). As such,
method and rater variance should be accounted for when
interpreting the correlations between BNSS scores and
measures of anhedonia and apathy.
Conclusions
The outcome of this study suggest that the BNSS can be
used to assess negative symptoms across different languages
Table 4 Discriminant validity
PANSS positive PANSS depressed PANSS disorganized PANSS excited CDSS MSASa
BNSS total -0.02 0.02 0.37** 0.19 0.16 0.12
SANS total 0.07 0.14 0.42** 0.29* 0.22 0.10
PANSS negative -0.01 0.16 0.41** 0.30** 0.26 0.15
BNSS anhedonia -0.13 -0.05 0.23 0.07 0.08 0.21
an = 56
*p < 0.05; **p < 0.01
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and health care systems. Furthermore, our data show that
convergent validity extends to self-ratings of anhedonia and
observer-ratings of apathy. Overall, the BNSS is a promising
instrument for the investigation of pathophysiological
mechanisms underlying the negative symptoms of schizo-
phrenia and particularly the two dimensions apathy/
avolition and diminished expression. Most importantly, it
allows assessment of negative symptoms across cultures
and thus could possibly be of use in future international
multicenter trials that target negative symptoms.
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